{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:26:44Z","timestamp":1787315204641,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005268","name":"Queensland Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2026628"],"award-info":[{"award-number":["APP2026628"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2019056"],"award-info":[{"award-number":["APP2019056"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2001396"],"award-info":[{"award-number":["APP2001396"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP220103135"],"award-info":[{"award-number":["DP220103135"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["IH220100017"],"award-info":[{"award-number":["IH220100017"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["LP220100450"],"award-info":[{"award-number":["LP220100450"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011025","name":"Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015572","name":"National Imaging Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008914","name":"Queensland Government Advance Queensland","doi-asserted-by":"publisher","award":["AQIRF094-2023RD6"],"award-info":[{"award-number":["AQIRF094-2023RD6"]}],"id":[{"id":"10.13039\/501100008914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001047","name":"Ian Potter Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000947","name":"Australian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029674","name":"A. C. Ratshesky Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005278","name":"North American Interfraternal Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114708","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:07:25Z","timestamp":1770826045000},"page":"114708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies"],"prefix":"10.1016","volume":"392","author":[{"given":"Nicholas L.","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pie","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Silveira E Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristofer J.","family":"Thurecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jconrel.2026.114708_bb0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.114708_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S25537","article-title":"Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease","volume":"5","author":"Harrison","year":"2013","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0015","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.1038\/s41598-019-48298-8","article-title":"The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier","volume":"9","author":"Kruijff","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114708_bb0020","article-title":"Alpha atlas: mapping global production of \u03b1-emitting radionuclides for targeted alpha therapy","volume":"142-143","author":"Tosato","year":"2025","journal-title":"Nucl. Med. Biol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114708_bb0025","doi-asserted-by":"crossref","first-page":"16974","DOI":"10.1021\/acsnano.1c09139","article-title":"Nanoparticles for Cancer diagnosis, radionuclide therapy and Theranostics","volume":"15","author":"Llop","year":"2021","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114708_bb0030","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114708_bb0035","doi-asserted-by":"crossref","unstructured":"Jarrett, T. R.; Pregelj, L.; Bell, C. A.; Fletcher, N. L.; Thurecht, K. J. Material trends and clinical costings in systematically identified CDER-approved nanomedicines. Adv. Ther. n\/a (n\/a), 2400124. DOI: https:\/\/doi.org\/10.1002\/adtp.202400124.","DOI":"10.1002\/adtp.202400124"},{"issue":"18","key":"10.1016\/j.jconrel.2026.114708_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/marc.202000319","article-title":"Next-generation polymeric nanomedicines for oncology: perspectives and future directions","volume":"41","author":"Fletcher","year":"2020","journal-title":"Macromol. Rapid Commun."},{"issue":"82","key":"10.1016\/j.jconrel.2026.114708_bb0045","doi-asserted-by":"crossref","first-page":"11538","DOI":"10.1039\/C8CC05831H","article-title":"Designed multifunctional polymeric nanomedicines: long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials","volume":"54","author":"Fletcher","year":"2018","journal-title":"Chem. Commun. (Camb.)."},{"issue":"57","key":"10.1016\/j.jconrel.2026.114708_bb0050","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.1039\/D2CC02443H","article-title":"Pre-targeting of polymeric nanomaterials to balance tumour accumulation and clearance","volume":"58","author":"Fletcher","year":"2022","journal-title":"Chem. Commun."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114708_bb0055","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1021\/acscentsci.9b01299","article-title":"Understanding the uptake of nanomedicines at different stages of brain Cancer using a modular nanocarrier platform and precision bispecific antibodies","volume":"6","author":"Houston","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114708_bb0060","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1021\/acs.molpharmaceut.2c00528","article-title":"Modulating macrophage clearance of nanoparticles: comparison of small-molecule and biologic drugs as pharmacokinetic modifiers of soft nanomaterials","volume":"19","author":"Mills","year":"2022","journal-title":"Mol. Pharm."},{"issue":"30","key":"10.1016\/j.jconrel.2026.114708_bb0065","first-page":"19890","article-title":"Mitigating the effects of persistent Antipolymer immune reactions in nanomedicine: evaluating materials-based approaches using molecular imaging","volume":"18","author":"Humphries","year":"2024","journal-title":"ACS Nano"},{"issue":"37","key":"10.1016\/j.jconrel.2026.114708_bb0070","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1016\/j.biomaterials.2014.08.032","article-title":"One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles","volume":"35","author":"Kao","year":"2014","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/acsnano.4c05906","article-title":"pH-responsive polyethylene glycol engagers for enhanced brain delivery of PEGylated nanomedicine to treat glioblastoma","volume":"19","author":"Meng","year":"2025","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15507","article-title":"Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy","volume":"8","author":"Su","year":"2017","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114708_bb0085","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/adhm.201600263","article-title":"Overcoming instability of antibody-nanomaterial conjugates: next generation targeted nanomedicines using bispecific antibodies","volume":"5","author":"Howard","year":"2016","journal-title":"Adv. Healthc. Mater."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114708_bb0090","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1021\/acs.biomac.3c00138","article-title":"Development and validation of a targeted treatment for brain tumors using a multi-drug loaded, relapse-resistant polymeric theranostic","volume":"24","author":"Chu","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114708_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121416","article-title":"Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption","volume":"283","author":"Janowicz","year":"2022","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114708_bb0100","article-title":"Investigation of the therapeutic potential of a synergistic delivery system through dual controlled release of Camptothecin\u2013Doxorubicin","volume":"3","author":"Zhao","year":"2020","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114708_bb0105","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1039\/D0SC00078G","article-title":"Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery","volume":"11","author":"Ediriweera","year":"2020","journal-title":"Chem. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114708_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801607","article-title":"Modulating targeting of poly(ethylene glycol) particles to tumor cells using bispecific antibodies","volume":"8","author":"Cui","year":"2019","journal-title":"Adv. Healthc. Mater."},{"issue":"20","key":"10.1016\/j.jconrel.2026.114708_bb0115","doi-asserted-by":"crossref","first-page":"17119","DOI":"10.1021\/acsomega.2c00620","article-title":"Investigation of a dual siRNA\/chemotherapy delivery system for breast Cancer therapy","volume":"7","author":"Zhao","year":"2022","journal-title":"ACS Omega"},{"issue":"12","key":"10.1016\/j.jconrel.2026.114708_bb0120","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1021\/acs.molpharmaceut.3c00558","article-title":"Targeted hyperbranched nanoparticles for delivery of doxorubicin in breast Cancer brain metastasis","volume":"20","author":"Lim","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114708_bb0125","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.2147\/IJN.S450534","article-title":"EGFR targeting of liposomal doxorubicin improves recognition and suppression of non-small cell lung cancer","volume":"19","author":"Moles","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jconrel.2026.114708_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123089","article-title":"Immune-modulating nanomedicines for enhanced drug delivery to non-small-cell lung cancer","volume":"317","author":"Liu","year":"2025","journal-title":"Biomaterials"},{"issue":"696","key":"10.1016\/j.jconrel.2026.114708_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1262","article-title":"Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia","volume":"15","author":"Moles","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114708_bb0140","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jconrel.2024.02.007","article-title":"Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma","volume":"367","author":"Logan","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114708_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-025-01926-z","article-title":"Balancing stealth and targeting to improve nanomedicine efficacy","author":"Ju","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114708_bb0150","doi-asserted-by":"crossref","first-page":"13739","DOI":"10.1021\/acsnano.0c06033","article-title":"Controlling the biological fate of micellar nanoparticles: balancing stealth and targeting","volume":"14","author":"Sivaram","year":"2020","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.jconrel.2026.114708_bb0155","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1039\/C9BM00957D","article-title":"Polymer design and component selection contribute to uptake, distribution & trafficking behaviours of polyethylene glycol hyperbranched polymers in live MDA-MB-468 breast cancer cells","volume":"7","author":"Simpson","year":"2019","journal-title":"Biomater. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114708_bb0160","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2967\/jnumed.112.115840","article-title":"A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry","volume":"54","author":"Zeglis","year":"2013","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2967\/jnumed.123.266388","article-title":"(212)pb-Pretargeted Theranostics for pancreatic cancer","volume":"65","author":"Bauer","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114708_bb0170","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1039\/D4BM01387E","article-title":"Harnessing nanoparticles and bioorthogonal chemistries for improving precision of nuclear medicine","volume":"13","author":"Ediriweera","year":"2025","journal-title":"Biomater. Sci."},{"issue":"27","key":"10.1016\/j.jconrel.2026.114708_bb0175","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1039\/D2PY00257D","article-title":"Development of targeted micelles and polymersomes prepared from degradable RAFT-based diblock copolymers and their potential role as nanocarriers for chemotherapeutics","volume":"13","author":"Ahmed","year":"2022","journal-title":"Polym. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114708_bb0180","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","article-title":"An overview of targeted alpha therapy","volume":"33","author":"Kim","year":"2012","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114708_bb0190","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2125.2009.03492.x","article-title":"Panitumumab","volume":"68","author":"Dubois","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114708_bb0195","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/mt.2015.178","article-title":"Receptor crosslinking: a general method to trigger internalization and lysosomal targeting of therapeutic receptor:ligand complexes","volume":"23","author":"Moody","year":"2015","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114708_bb0200","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.7150\/jca.32470","article-title":"Strategic trastuzumab mediated crosslinking driving concomitant HER2 and HER3 endocytosis and degradation in breast Cancer","volume":"11","author":"Wymant","year":"2020","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-57153-9","article-title":"Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation","volume":"10","author":"Jones","year":"2020","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114708_bb0210","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jcmm.12899","article-title":"A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2","volume":"20","author":"Szymanska","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114708_bb0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2019.12.049","article-title":"Multivalent HER2-binding polymer conjugates facilitate rapid endocytosis and enhance intracellular drug delivery","volume":"319","author":"Radford","year":"2020","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114708_bb0220","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.nucmedbio.2013.01.010","article-title":"Methodology for labeling proteins and peptides with lead-212 (212Pb)","volume":"40","author":"Baidoo","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2026.114708_bb0225","doi-asserted-by":"crossref","DOI":"10.1039\/D4QI01338G","article-title":"Rapid and stable complexation of the \u03b1-generators bismuth-212 and lead-212 with a tetraazamacrocyclic chelator bearing thiosemicarbazone pendant arms","author":"Grieve","year":"2024","journal-title":"Inorg. Chem. Front."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114708_bb0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijrobp.2003.09.028","article-title":"Phosphorylation of histone H2AX as a measure of radiosensitivity","volume":"58","author":"Olive","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0235","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40658-022-00481-z","article-title":"Quantitative SPECT\/CT imaging of lead-212: a phantom study","volume":"9","author":"Kvassheim","year":"2022","journal-title":"EJNMMI Phys."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114708_bb0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40658-023-00571-6","article-title":"Imaging of 212Pb in mice with a clinical SPECT\/CT","volume":"10","author":"Kvassheim","year":"2023","journal-title":"EJNMMI Phys."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114708_bb0245","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2967\/jnumed.123.267189","article-title":"First-in-human (212)pb-PSMA-targeted \u03b1-therapy SPECT\/CT imaging in a patient with metastatic castration-resistant prostate Cancer","volume":"65","author":"Griffiths","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114708_bb0250","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.7150\/thno.11742","article-title":"Current approaches for improving Intratumoral accumulation and distribution of nanomedicines","volume":"5","author":"Durymanov","year":"2015","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.jconrel.2026.114708_bb0255","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1038\/s41596-021-00540-2","article-title":"Inverse electron demand Diels\u2013Alder click chemistry for pretargeted PET imaging and radioimmunotherapy","volume":"16","author":"Sarrett","year":"2021","journal-title":"Nat. Protoc."},{"issue":"45","key":"10.1016\/j.jconrel.2026.114708_bb0260","doi-asserted-by":"crossref","first-page":"28316","DOI":"10.1073\/pnas.2009960117","article-title":"Harnessing (64)cu\/(67)cu for a theranostic approach to pretargeted radioimmunotherapy","volume":"117","author":"Kein\u00e4nen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114708_bb0265","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1021\/acs.molpharmaceut.5b00294","article-title":"Optimization of a Pretargeted strategy for the PET imaging of colorectal carcinoma via the modulation of radioligand pharmacokinetics","volume":"12","author":"Zeglis","year":"2015","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114708_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"Wu","year":"2021","journal-title":"J. Pers. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114708_bb0275","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/pharmaceutics14040731","article-title":"Hematological toxicity in mice after high activity injections of 177Lu-PSMA-617","volume":"14","author":"Kristiansson","year":"2022","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.jconrel.2026.114708_bb0280","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/MNM.0b013e328354df7c","article-title":"Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts","volume":"33","author":"Abbas","year":"2012","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.jconrel.2026.114708_bb0285","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.biomaterials.2017.07.004","article-title":"Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic","volume":"141","author":"Pearce","year":"2017","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114708_bb0290","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7150\/ntno.27142","article-title":"In vivo therapeutic evaluation of polymeric nanomedicines: effect of different targeting peptides on therapeutic efficacy against breast cancer","volume":"2","author":"Zhao","year":"2018","journal-title":"Nanotheranostics"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:33:46Z","timestamp":1787128426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":58,"alternative-id":["S0168365926001100"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114708","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114708"}}